Budillon G, Cimino L, Del Vecchio Blanco C, Mazzacca G, Iaquinto G, D'Ascoli B, Lampasi F, Di Sapio M, Mattera D, Sapio D [corrected to Di Sapio M ]
II Cattedra Gastroenterologia, Università di Napoli, Italy.
Ital J Gastroenterol. 1994 Jan-Feb;26(1):16-20.
In a long-term study (27 months) of patients affected by C-virus active hepatitis we have evaluated the effect of decreasing the dose of interferon by 50% and by 75% with respect to the initial efficacious dose (6 MU tiw). Sixty patients received recombinant interferon alpha-2b(r-IFN- alpha-2b) 6 MU tiw for two months followed by 3 MU for seven months (Group A), and 60 patients received r-IFN alpha-2b 6 MU tiw for two months followed by 1.5 MU for seven months (Group B). Three patients in group B failed to return to follow-up and were not considered in subsequent evaluations. Side effects such as to cause suspension of treatment occurred only during the first two months of the study at 6 MU of interferon (3 patients in group A and 6 in group B). During the two months at 6 MU, transaminase values returned to normal in 94 patients (80%). At the end of follow-up, 49 of these patients (42% of the 117 patients examined; or 48.3% in group A and 35.1% in group B) had normal transaminase levels. In no case did the anti-HCV test become negative. On a reduced dose of interferon, relapses occurred more frequently in group B (21.4%) than in group A (9.6%), but the difference was not significant. No difference between responders and non-responders, including relapsing patients, was observed in relation to gender, age, presence of cirrhosis, presence of B-virus antibodies and initial levels of serum transaminase.
在一项针对丙型肝炎活动性肝炎患者的长期研究（27个月）中，我们评估了相对于初始有效剂量（6MU，每周三次）将干扰素剂量降低50%和75%的效果。60名患者接受重组干扰素α-2b（r-IFN-α-2b）6MU，每周三次，持续两个月，随后7个月接受3MU（A组），60名患者接受r-IFNα-2b 6MU，每周三次，持续两个月，随后7个月接受1.5MU（B组）。B组有3名患者未返回接受随访，后续评估未将其纳入。仅在研究的前两个月，当干扰素剂量为6MU时，出现了导致治疗中断的副作用（A组3例，B组6例）。在6MU治疗的两个月期间，94名患者（80%）的转氨酶值恢复正常。随访结束时，这些患者中有49名（占检查的117名患者的42%；A组为48.3%，B组为35.1%）转氨酶水平正常。抗-HCV检测在任何情况下均未转为阴性。在较低剂量的干扰素治疗下，B组（21.4%）的复发频率高于A组（9.6%），但差异不显著。在应答者和无应答者之间，包括复发患者，在性别、年龄、肝硬化的存在、B病毒抗体的存在以及血清转氨酶的初始水平方面未观察到差异。
